The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Studying the genetics of CLL to prevent Richter’s transformation
Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. He discusses how the genetics of chronic lymphocytic leukemia (CLL) impacts outcome in patients, with particular reference to IGHV, TP53 and MYC mutations. He talks about strategies to prevent Richter’s transformation using existing and novel treatments.
